Per the U.S. DoD, * Indicates a "small business" classification and ** indicates a "small disadvantaged business". NOTE: the U.S. DoD only publicly reports contracts valued at $6.5 million USD or greater.
The contract language is EXACTLY as it appears on the official U.S. DoD website (http://www.defense.gov/contracts/) unless otherwise noted.
Contractor: Sanofi Pasteur VaxDesign Corporation
Department: Defense Threat Reduction Agency
Sanofi Pasteur VaxDesign Corporation of Orlando, Fla., is being awarded a $15,106,789 cost-plus fixed-fee, incrementally-funded contract for research and development services for the Defense Threat Reduction Agency (DTRA) to further optimize and utilize the invitro biomimetic immune system. The contract award was a direct response to DTRA's Chem-Bio Broad Agency Announcement. Work will be performed in Orlando, Fla., and at the U.S. Army Medical Research Institute of Infectious Diseases (ASAMRIID) at Fort Detrick, Md., and is expected to be completed March 24, 2017. Fiscal 2012 Research, Development, Testing and Evaluation funds in the amount of $1,406,191 will be used to incrementally fund this effort at award. The contracting activity is Defense Threat Reduction Agency, Fort Belvoir, Va., (HDTRA1-13-C-0011).
Total Contract Value: $15,106,789